SCHEMBL3823937

SCHEMBL3823937

CCOC(=O)CCCC(C(=O)COC)C(=O)c1cncc(C)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 2/20 0.42
CYP1A2 P05177 2/20 0.42
CYP3A4 P08684 1/20 0.42
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 2/20 0.42
HPGD P15428 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
ATM Q13315 1/20 0.40
HSD17B10 Q99714 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
HCAR2 Q8TDS4 1/20 0.37
TBXAS1 P24557 4/20 0.35
CYP2C9 P11712 1/20 0.35
CYP4F2 P78329 1/20 0.33
CYP4A11 Q02928 1/20 0.33
KMT2A Q03164 3/20 0.32
POLB P06746 1/20 0.32
MEN1 O00255 1/20 0.31
NLRP3 Q96P20 1/20 0.31
TNF P01375 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3821381 0.97 CYP2C19 (0.42) CYP2C19CYP1A2CYP3A4KDM4EALDH1A1
SCHEMBL3824981 0.93 KDM4E (0.43) CYP2C19CYP1A2CYP3A4KDM4EALDH1A1
SCHEMBL3819407 0.91 CYP2C19 (0.42) CYP2C19CYP1A2CYP3A4KDM4EALDH1A1
SCHEMBL3819727 0.90 CYP1A2 (0.55) CYP2C19CYP1A2CYP3A4KDM4EALDH1A1
SCHEMBL3829451 0.89 CYP2C19 (0.41) CYP2C19CYP1A2CYP3A4KDM4EALDH1A1
SCHEMBL3825654 0.89 CYP2C19 (0.41) CYP2C19CYP1A2CYP3A4KDM4EALDH1A1
SCHEMBL3819374 0.88 CYP2C19 (0.42) CYP2C19CYP1A2CYP3A4KDM4EALDH1A1
SCHEMBL3826740 0.87 CYP1A2 (0.54) CYP2C19CYP1A2CYP3A4KDM4EALDH1A1
SCHEMBL3823338 0.86 CYP2C19 (0.46) CYP2C19CYP1A2CYP3A4KDM4EALDH1A1
SCHEMBL3822080 0.86 CYP2C19 (0.40) CYP2C19CYP1A2CYP3A4KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1581535-B3 PYRROLOPYRIDAZINE DERIVATIVES ASTELLAS PHARMA INC (JP) 2009-09-02 EP disclosed
EP-1581535-B9 PYRROLOPYRIDAZINE DERIVATIVES ASTELLAS PHARMA INC (JP) 2008-03-19 EP disclosed
US-7317009-B2 Pyrrolopyridazine derivatives ASTELLAS PHARMA INC. (JP) 2008-01-08 US disclosed
EP-1581535-B1 PYRROLOPYRIDAZINE DERIVATIVES ASTELLAS PHARMA INC (JP) 2007-10-24 EP disclosed
US-7153854-B2 Pyrrolopyridazine derivatives ASTELLAS PHARMA INC. (JP) 2006-12-26 US disclosed
US-20060270678-A1 Pyrrolopyridazine derivatives ASTELLAS PHARMA INC. (JP) 2006-11-30 US disclosed
EP-1581535-A1 PYRROLOPYRIDAZINE DERIVATIVES Astellas Pharma Inc. (JP) 2005-10-05 EP disclosed
US-20050075342-A1 Pyrrolopyridazine derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-04-07 US disclosed
WO-2004063197-A1 PYRROLOPYRIDAZINE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050075342-A1 Pyrrolopyridazine derivatives PDE4A, PDE5A, PDE12 CYP2C19 867/4885CYP1A2 367/4885CYP3A4 202/4885
US-20060270678-A1 Pyrrolopyridazine derivatives PDE4A, PDE5A, PDE12 CYP2C19 867/4885CYP1A2 367/4885CYP3A4 202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.